

2nd Conference on Antiviral Substances

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

VOLUME 173 ARTICLE 1 PAGES 1-844

(THIS ARTICLE COMPLETES VOLUME 173)

July 25, 1970

SECOND CONFERENCE ON ANTIVIRAL SUBSTANCES*

Editors and Conference Cochairmen

ERNEST C. HERRMANN, JR. AND WARREN R. STINEBRING

CONTENTS

Introductory Remarks. By Ernest C. Herrmann, Jr.	9
PART I. CLINICAL USEFULNESS OF ESTABLISHED ANTIVIRAL DRUGS	
Evaluation of Amantadine Hydrochloride in the Treatment of A ₂ Influenza Disease. By Richard B. Hornick, Yasushi Togo, Sara Mahler and Domenic Iezzoni.....	10
The Effect of Iodo-deoxyuridine on Herpes Simplex Virus Encephalitis in Animals and Man. By H. Tomlinson and F. O. MacCallum.....	20
Protective Effect of Aminoadamantane on Influenza A ₂ Infections in the Family Environment. By A. W. Galbraith, J. S. Oxford, G. C. Schild and G. I. Watson.....	29
The Prospect of Amantadine for Prevention of Influenza A ₂ in Humans (Effectiveness of Amantadine during Influenza A ₂ / Hong Kong Epidemics in January-February, 1969 in Leningrad). By Anatoli A. Smorodintsev, George I. Karpuchin, Dimitry M. Zlydnikov, Anna M. Malysheva, Evgenya G. Shvetsova, Sergey A. Burov, Lidia M. Chramtsova, Yury A. Romanov, Ludmila Yu. Taros, Yury G. Ivannikov and Sergey D. Novoselov.....	44
Field Studies with Amantadine: Acceptability and Protection. By Robert O. Peckinpugh, Frederick B. Askin, Willard E. Pierce, Earl A. Edwards, David P. Johnson and George G. Jackson.....	62
Results of the Treatment of Zoster with Idoxuridine in Dimethyl Sulfoxide. By B. E. Juel-Jensen.....	74
Topical Idoxuridine in Recurrent Herpes Simplex, with a Note on Its Effect on Early Varicella. By Sidney Kibrick and Alan S. Katz.....	83
The Effect of Idoxuridine on the Excretion of Cytomegalovirus in Congenital Infection. By B. W. Barton and J. C. H. Tobia.....	90
Antiviral Properties of Idoxuridine (IUDR) during Steroid Treat- ment of Herpes Stromal Keratitis. By Samuel B. Aronson and Thomas E. Moore, Jr.	96

*This series of papers is the result of a conference entitled
Second Conference on Antiviral Substances, held by The New York
Academy of Sciences on June 16-19, 1969.

Factors Influencing Controlled Clinical Drug Evaluation in Self-Limiting Disease. By Jurg A. Schneider, Domenic G. Iezzoni and Sara A. Mahler.....	103
Effectiveness of Amantadine in Protecting Vaccinated Volunteers from an Attenuated Strain of Influenza A ₂ /Hong Kong Virus. By Miha Likar.....	108
Discussion. Leonard Hayflick, <u>Session Chairman</u>	113

PART II. NEWER METHODS IN THE STUDY OF ANTIVIRAL AGENTS

Purification and Properties of Human Interferon. By Karl H. Fantes.....	118
Experimental Methodology and the Search for Effective Antiviral Agents. By E. Grunberg and Herbert N. Prince.....	122
Methods for Screening <u>In Vitro</u> and <u>In Vivo</u> for Agents Active against Myxoviruses. By N. B. Finter.....	131
Quantitative Assessment of Virus Inhibition by Indirect Techniques <u>In Vivo</u> . By Claire G. Engle, Jack W. Frankel and Justus Gelzer.....	139
Rapid Semi-Automated Procedures for Assaying Antiviral Activity. By P. A. Miller, H. L. Lindsay, M. Cormier, B. R. Mayberry and P. W. Trown.....	151
Attempts to Prepare Interferon in Continuous Cultures of Human Leukocytes. By Kari Cantell.....	160
Intranasal Toxicity Testing of Antiviral Agents. By G. A. Elliott and E. N. DeYoung.....	169
The Effect of Cell-Free Extracts on the Inhibition of Virus Multiplication by 6-Azauridine. By B. Rada.....	176
Viral Polymerase Proteins as Antiviral Agents (Intrinsic Interference). By Philip I. Marcus and Harriet L. Zuckerbraun...	185
Discussion. Lionel E. Rhuland, <u>Session Chairman</u>	199

PART III. THE FUTURE--ANTIVIRAL DRUGS OR VACCINES?

Respiratory Disease: The Current Target for Antiviral Therapy. By Joel Warren.....	203
The Future--Antiviral Drugs or Vaccines? A Comparison of Their Relative Contributions to the Future of Disease Control. By B. A. Rubin.....	206
The Future: Antiviral Drugs or Vaccines. By Richard F. Haff..	210
Purine and Pyrimidine Nucleosides as Antiviral Agents--Recent Developments. By Frank M. Schabel, Jr.	215
The Future--Antiviral Drugs or Vaccines? Panel Discussion. Ernest C. Herrmann, Jr., <u>Session Chairman</u>	221
<u>Copyright, 1970, by The New York Academy of Sciences. All rights reserved. Except for brief quotations by reviewers, reproduction of this publication in whole or in part by any means whatever is strictly prohibited without written permission from the publisher.</u>	

PART IV. LABORATORY STUDIES OF ANTIVIRAL AGENTS

A Gene with Quantitative Effect on Circulating Interferon Induction--Further Studies. By E. De Maeyer and Jaqueline De Maeyer-Guignard.....	228
The Evaluation of Compounds against Influenza Viruses. By Sydney L. Squires.....	239
Interferon Production in Mice by Cell Wall Mutants of <u>Salmonella Typhimurium</u> . III. Role of Lipid Moiety of Bacterial Lipopolysaccharide in Interferon Production in Animals. By David Sidney Feingold, Julius S. Youngner and Joseph Chen.....	249
The Antiviral Activity of 3,4-Dihydro-1-Isoquinolineacetamide Hydrochloride on Columbia SK Virus Infection in Mice and Tissue Culture. By Brian R. Murphy and Lowell A. Glasgow...	255
The Interferon Inducer from Brucella. By P. De Somer, E. De Clercq, C. Cocito and A. Billiau.....	274
The Dynamics of IUDR Action in Herpetic Keratitis and the Emergence of IUDR Resistance <u>In Vivo</u> . By Ernest Javetz, Virginia R. Coleman, Chandler R. Dawson and Phillips Thygeson	282
Decalins--a New Class of Compounds Active against Influenza A Viruses. By D. L. Swallow, P. N. Edwards and N. B. Finter..	292
Passage of Influenza Strains in the Presence of Aminoadamantane. By J. S. Oxford, I. S. Logan and C. W. Potter.....	300
Activity of Methisazone against RNA Viruses. By D. J. Bauer, K. Apostolov and J. W. T. Selway.....	314
Interferon Production in Leukocytes and the Antiviral Protection of Mice Treated with Endotoxin. By Ladislav Borecky, Vladimir Lackovic and Gustav Russ.....	320
Discussion. Conrad E. Hoffmann, <u>Session Chairman</u>	331

PART V. MECHANISM OF ACTION

The Action of Poly I·C·r on the RNA Metabolism of Cultured Cells. By Sam A. Margolis and Hilton B. Levy.....	339
Nucleoside Analogues as Chemotherapeutic Antiviral Agents. By Albert S. Kaplan and Tamar Ben-Porat.....	346
The Effects of Interferon on Vaccinia Virus Infection in Tissue Culture. By Wayne E. Magee and Seymour Levine.....	362
The Relation of Antiviral Activity of IUDR to Gene Function in Phage. By Barry Goz and William H. Prusoff.....	379
Metabolic Determinants of the Induction of Interferon by Synthetic Double-Stranded Polynucleotide in Rabbit Kidney Cells. By Jan Vilcek.....	390
Specific Inhibitor for RNA Replicase. By Ichiro Haruna, Itaru Watanabe, Yujiro Yamada and Kozo Nagaoka.....	404
Inhibition of Early Stages of Virus-Cell Interactions. By Hans J. Eggers.....	417

Effects of Guanidine on the Biosynthesis of Poliovirus. By Lawrence A. Caligiuri and Igor Tamm.....	420
Tritium-Labelled L Cell Interferon: Further Characterization and Purification by Electrophoresis in Polyacrylamide Gels. By Daniel Stancek and Kurt Paucker.....	427
Inhibitors of Influenza Virus-Induced RNA Polymerase. By Peter P. K. Ho and C. Patricia Walters.....	438
PART VI. POTENTIAL ANTIVIRAL DRUGS (1)	
Structural Requirements for Synthetic Polyanions to Act as Inter- feron Inducers. By E. De Clercq, F. Eckstein and T. C. Merigan.....	444
Laboratory Studies on Two Synthetic Dihydroisoquinolines (Pfizer UK.2054 and UK 2371). By J. D. Coombes, K. W. Brammer, Ruth H. Herbst-Laier, N. M. Larin, C. R. McDonald, M. S. Tute, E. Anne Wickham and G. M. Williamson.....	462
Progress in Rhinovirus Chemotherapy. By John J. Boyle, W. G. Raupp, F. J. Stanfield, Richard F. Haff, Elliot C. Dick, Donn D'Alessio and Claire R. Dick.....	477
Sensitivity of Rabbit Cells to Primate Interferons. By Jan Desmyter, William E. Rawls and Joseph L. Melnick.....	492
Interferon Regulatory Mechanism. By C. Chany, F. Fournier and S. Rousset.....	505
Preclinical Studies with 5-(3,4-Dichlorophenyl)-5-ethyl-hexahy- dropyrimidine-2,4,6-trione. By Donald C. DeLong, Wilbur J. Doran, Linville A. Baker and Janet D. Nelson.....	516
Antiviral Studies with Kethoxal. By H. E. Renis.....	527
Interferon Stimulation by Low Molecular Weight Polyacrylic Acids. By John F. Niblack.....	536
Order Specificity of Certain Avian Interferons. By Joan M. Moehring and Warren R. Stinebring.....	538
Discussion. Jan Vilcek, <u>Session Chairman</u>	543
<u>In Vitro and In Vivo</u> Studies with Statolon against Influenza Virus. By Walter J. Kleinschmidt.....	547
Influenza Infections of Mice. II. Curative Activity of α -Methyl-1-adamantanemethylamine HCl (Rimantadine HCl). By J. W. McGahen, E. M. Neumayer, R. R. Grunert and C. E. Hoffmann.....	557
Induction of Interferon and Viral Resistance in Animals by Polynucleotides. By S. Baron, H. duBuy, C. E. Buckler, M. L. Johnson, J. Park, A. Billiau, P. Sarma and R. J. Huebner.....	568
Suppression and Emergence of Established Friend Virus Leukemia: Clinical Remission after Statolon Treatment. By E. Frederick Wheelock and Nancy L. Caroline.....	582
Comparison of the Anticytomegalovirus Activity of a Group of	

Pyrimidine Analogs. By Robert W. Sidwell, Gussie Arnett and R. Wallace Brockman.....	592
Thiazolidines, a New Group of Antiviral Substances. By Primoz Schauer, Miha Likar and Slava Klemenc-Sebek.....	603
Effect of Poly I:C in Mice Injected with Japanese B Encephalitis Virus. By Bosko Postic and Gladys E. Sather.....	606
Discussion. Charles Chany, <u>Session Chairman</u>	614
PART VII. WILL INTERFERON BE CLINICALLY USEFUL?	
Will Interferon Be Clinically Useful? By N. B. Finter.....	619
Some Preclinical Studies in Animal Models with Double-Stranded RNA's. By Maurice R. Hilleman.....	623
Will Interferon Be Clinically Useful? Discussion. By Leonard Hayflick.....	629
Will Interferon Be Clinically Useful? Panel Discussion. Warren R. Stinebring, <u>Session Chairman</u>	631
PART VIII. POTENTIAL ANTIVIRAL DRUGS (2)	
The Mechanism of the Antitumor Action of Poly I:Poly C. By Hilton B. Levy, Richard Asofsky, Freddie Riley, Axel Garapin, Harvey Cantor and Richard Adamson.....	640
The Relationship between Virus Chemotherapy, Secretory Antibody Formation and Recurrent Herpetic Disease. By Y. M. Centifanto, J. M. Little and H. E. Kaufman.....	649
Influence of Basic Substances on the Induction of the Interferon Mechanism. By Alfons Billiau, Charles E. Buckler, Ferdinando Dianzani, Carol Uhlendorf and Samuel Baron.....	657
The Higher Plants with Antiviral and Antilethal Activity on Virus Infections in Mice. By Eiichi Furusawa and Windsor Cutting.....	668
The Effect of Preinjections on the Stimulation of Interferon by a Complexed Polynucleotide, Endotoxin and Virus. By Monto Ho, Mary K. Breinig, Bosko Postic and John A. Armstrong.....	680
Treatment of Neoplasia in Mice with Interferon Preparations. By Ion Gresser, Chantal Bourali, Ivan Chouroulinkov, Daniele Fontaine-Brouty-Boye and Marie-Therese Thomas.....	694
Antiviral Action of 2-Thiouridine. By Libor Slechta and James H. Hunter.....	708
Production of Interferon Following an Immune Response. By Warren R. Stinebring and P. Marlene Absher.....	714
A Mushroom Extract as an Interferon Inducer. By Akira Tsunoda and Nakao Ishida.....	719
Studies on the Potentiating Effect of DEAE-Dextran on Interferon Production Induced by Double-Stranded Synthetic Polynucleotides. By F. Dianzani, S. Gagnoni and P. Cantagalli.....	727
Immune Stimulation of Interferon in Human Leucocyte Cultures by	

Non-Viral Antigens. By Jon Allen Green, Sidney R. Cooperband, Lawrence F. Kleinman and Sidney Kibrick.....	736
Discussion. D. John Bauer, <u>Session Chairman</u>	742
PART IX. CLINICAL EVALUATION OF NEWER ANTIVIRAL AGENTS	
Clinical Studies Employing Interferon Inducers in Man and Animals. By T. C. Merigan, E. De Clercq, M. S. Finkelstein, L. Clever, S. Walker and D. J. Waddell.....	746
Studies of Isoquinoline Derivatives (U.K.2371 and U.K.2054) in Respiratory Infections of Volunteers, Using Influenza Viruses a Parainfluenza Virus and a Rhinovirus. By Sylvia E. Reed, A. S. Beare, M. L. Bynoe and D. A. J. Tyrrell.....	760
Progress towards Trials of Human Interferon in Man. By R. D. Andrews, G. Appleyard, A. J. Beale, R. A. Bucknall, K. Cantell, M. Clarke, E. M. B. Clements, C. C. Draper, K. H. Fantes, N. B. Finter, H. Nevanlinna, F. T. Perkins, D. A. J. Tyrrell and A. Whittaker.....	770
Clinical Evaluation of 4'-[2-Nitro-1-(p-tolylthio)ethyl]acetanilide (U-3243) against Cutaneous Herpes Simplex. By Gerald E. Underwood.....	782
Studies on Coxsackie A-21 (COE) Virus-Infected Volunteers: Effect of Local Therapy with Gamma Globulin. By D. A. Buthala, R. Damiano and E. E. Eidson.....	794
Potential New Agents for the Treatment of Viral Disease with Special Reference to the Respiratory Area. By Jerome A. Gold	808
Induction of Endogenous Interferon by Use of Standard Live Vaccines for Prevention of Respiratory Viral Infections. By Alexander A. Smorodintsev, Diana A. Gvozdilova, Yury A. Romanov, Georgy S. Makarjev, Valery I. Rudenko, Oleg A. Aksenov and Dimitry M. Zlydnikov.....	811
A Preliminary Study on Treatment of Human Herpes Simplex Keratitis with an Interferon Inducer. By Roberto Guerra, Renato Frezzotti, Raffaele Bonanni, Ferdinando Dianzani and Geo Rita.....	823
The Reticuloendothelial Effects of Interferon Inducers: Poly- anionic and Non-polyanionic Phylaxis against Microorganisms. By William Regelson and Albert E. Munson.....	831
Discussion. Herbert E. Kaufman, <u>Session Chairman</u>	842
Concluding Remarks. By Warren R. Stinebring.....	844

Publication of this monograph was made possible, in part,
with the assistance of:

ABBOTT LABORATORIES
ALLERGAN PHARMACUTICALS
BRISTOL LABORATORIES
BURROUGHS WELLCOME & CO., INC.
CHAS. PFIZER & CO., INC.
CIBA CORPORATION
DU PONT de NEMOURS & CO., INC.
ELI LILLY AND COMPANY
DR. E. C. HERRMANN, JR.
HOFFMANN-LA ROCHE, INC.
LABOUCHERE & CO., N.Y.
LEDERLE LABORATORIES
MERCK & CO., INC.
MICROBIOLOGICAL ASSOCIATES
MILES LABORATORIES, INC.
NORWICH EATON CHARITABLE TRUST
SCHERING A. G.
SCHERING CORPORATION
G. D. SEARLE & CO.
SMITH KLINE & FRENCH LABORATORIES
STERLING-WINTHROP RESEARCH INSTITUTE
THE UPJOHN CO.
UNION CARBIDE CORP.
WALLACE LABORATORIES
WARNER-LAMBERT RESEARCH INSTITUTE
WYETH LABORATORIES

INTRODUCTORY REMARKS

Ernest C. Herrmann, Jr.

Mayo Clinic and Mayo Foundation
Rochester, Minnesota

In December, 1964 the New York Academy of Sciences sponsored the first conference on Antiviral Substances that now in retrospect seems to have been a turning point into the antiviral era. At that time no less than three drugs were fully established to have a worthwhile influence on viral disease in man. Until that time, many had believed that a chemical attack on viral disease was not possible and vaccination was the only acceptable approach. In the last 54 months there has been a noticeable increase in interest and, what is more important, a substantial increase in effort in the antiviral area, with continuing disenchantment with the vaccine approach. I think it is reasonable to say that of those interested in solving the problem of viral disease most believe chemotherapy must be the wave of the future just as it was 35 years ago in bacterial diseases.

At our first conference, four and a half years ago, research on interferon had not been included. Although many fundamental studies had been done on interferon, it seemed at the time that little progress had been made toward possible use of this knowledge in human viral disease. There is now, however, considerable practical interest. Interferon will, therefore, as it should, take its place as another aspect of the antiviral field.

We have before us at this conference some significant questions. Will interferon or its chemical induction be a practical method to alleviate viral disease? What direction should antiviral studies take to be most productive? Is chemoprophylaxis a logistically practical approach? How readily can true chemotherapy be achieved? What indeed will the basic studies of antiviral agents contribute to the overall solution of the viral disease problem? Hopefully we can find some answers to these and many more questions that may well determine the destiny of the antiviral field for some time to come. We cannot any longer hold to the outworn and sentimental concepts. New ground was broken four and one half years ago and some rewards were harvested. At this conference we shall reaffirm the often unrecognized progress of the past and again further prove that what many said could not be done has been and is being done.

The contribution and interest of the New York Academy of Sciences in the antiviral field has been immeasurable. They took a gamble in December, 1964 and it resulted in a significantly successful conference. Again they have been extremely generous and cooperative in supporting this Second Conference on Antiviral Substances. There is some considerable doubt, however, that a conference of this size and scope could ever have been produced without the generous financial support of 27 commercial firms both here and overseas. It perhaps is some measure of the significance of the subject that so many were so willing to invest so much to see this conference come to pass.

On behalf of Dr. Stinebring and myself I therefore welcome you, encourage you to actively participate in the discussions and wish you a highly productive four days.

Evaluation of Amantadine Hydrochloride in the Treatment of A₂ Influenzal Disease

Richard B. Hornick, M.D., Yasushi Togo, M.D., Sara Mahler, M. D., and Domenic Iezzone, M.D. University of Maryland School of Medicine, Baltimore Maryland and E.I. duPont de Nemours Company, Wilmington, Delaware

The therapeutic utilization of antibiotics resulted in dramatic relief from the ravages of bacterial infections. As clinicians involved in the management of patients with viral infections we look forward to similar drugs useful in the control of such illnesses. Few viral infections presently prevalent in this country are life threatening; those previously dreaded such as polio and the childhood exanthemata (not necessarily benign) have been contained through the use of effective vaccines. This approach may be impractical with the very common respiratory viral diseases which are initiated by a constellation of individual viral agents. Although, immunoprophylaxis may be useful for selected agents that cause the more serious infections. Unfortunately, vaccines developed against influenza virus have several shortcomings and have not yet provided ultimate protection. Thus, it is against this array of respiratory viruses, responsible for significant morbidity, that a chemotherapeutic or chemoprophylactic drug would be useful. It is the purpose of this paper to summarize the data indicating a therapeutic effect of one drug, amantadine hydrochloride in the management of infections caused by influenza viruses of the A₂ variety.

Promise of potential usefulness of this antiviral agent was first entertained from results in tissue culture, eggs and mice some years ago.(1,2) The information from these studies plus many additional experiments have provided reliably prognostic value as to whether an effect will be attained in man.(3) Thus there does appear to be correlation between sensitivity to amantadine as demonstrated in eggs, tissue culture or mice and subsequent effectiveness of the drug in man against particular influenza strains. The prophylactic use of amantadine in volunteers with induced A₂ infections demonstrated first that incidence and severity of illness was reduced and serological evidence of infection was impaired in drug treated individuals. These studies implied that the drug was protecting susceptible cells from virus. The known action of amantadine is not virucidal but rather viral penetration through the cell membrane is prevented. (4) The presence of the drug prior to initiation of disease could protect many cells reducing the viral population and thereby aborting infection and hindering the production of antibodies. Whether drug given after infection had started could impede progression of disease remained to be elucidated. Early experiments conducted by Jackson, 1965, were designed to test efficacy of drug given 1/2 hour prior to or 3 hours after virus inoculation (5). The attenuated vaccine strain A₂ type employed in these studies was not inhibited in man when drug was administered at approximately the time of challenge. In contrast drug given 20 hours prior to challenge was extremely effective in preventing infection. Additional studies conducted in volunteers

using only susceptible individuals - that is men with low or absent titers of homologous circulating antibody to a virulent challenge strain of A₂ virus, confirmed the drug's prophylactic usefulness (6). These encouraging results prompted therapeutic trials to further test the action of the drug once infection had already become manifest. Early in January, 1968 A₂ influenza was documented in several areas of the country. Following a uniform protocol, studies were conducted in Virginia, Maryland, Texas and Missouri in prisoners ill with a influenza-like illness. A small number of patients from a Masonic home in St. Louis, Missouri were also enrolled. Febrile men who by history were ill less than 48 hours were asked to volunteer. Drug was assigned in a double-blind fashion and each volunteer received either 100 mgm amantadine or lactose as a placebo twice a day for 10 days. Physicians admitted patients to a hospital ward where they were kept until discharge. Temperature recordings were obtained every four hours and findings were recorded on check sheets listing common signs and symptoms of influenza. Examinations were conducted twice daily or at least once a day after the acute illness had abated. In each study serum specimens were obtained on admission and day 21. Throat and nasal swabs for virus isolation were obtained in all studies at least twice during the first 3 hospital days. In the 2 Texas prisons we made a concentrated effort to determine effect of amantadine on virus shedding and swabs were obtained daily for five days.

TABLE I

Mean time of start of study medications after onset
of influenza A₂ illness

	"Symmetrel" Groups		Placebo Groups	
	Hrs.	No.	Hrs.	No.
Walls, Texas	24.2	23	22.0	20
Wynne, Texas	23.7	17	21.8	17
Jessup, Maryland	19.6	12	22.7	15
Richmond, Virginia	15.6	21	15.0	28
Missouri State	20.7	12	24.9	8
Masonic Home (Mo.)	12.4	9	8.1	15
Total		94		103

The analysis of the results of the combined studies involved mainly clinical responses, temperature, antibody response and virus shedding. Only individuals with confirmed influenza either by four fold or greater rise in antibody titer or repeated virus isolation, were included. The first table outlines the areas where these studies were conducted and in addition the time interval between onset of illness and initiation of drug treatment. The figures represent only those men with confirmed influenza infection. Note the comparable time intervals for placebo and amantadine within the population groups.

TABLE II

Group* mean admission temperatures (F°)

	"Symmetrel"	Placebo
Walls Prison	100.9	101.3
Wynne Prison	100.9	101.1
Jessup Prison	101.3	101.9
Richmond Prison	101.5	101.0
Missouri State Prison	100.3	99.6
Masonic Home	100.4	100.4

*For study subjects with laboratory confirmation of influenza A₂

The second table lists the group mean temperature recordings at the time of admission to the study. The greatest mean variation between placebo and amantadine group was 0.7°F. The subsequent clinical response of these groups has been analyzed to determine whether amantadine had a beneficial effect. Our studies in the 2 Texas prisons and the Maryland prison convinced us that post treatment illness fell mainly into 2 categories. One in which there was a rapid clinical improvement and a second in which the response was delayed. Criteria were therefore established to categorize the majority of these cases and to account for those falling in between the two groups. Figure 1 lists the criteria for rapid, medium and slow responders and depicts the number of individuals from the 6 clinical trials that fitted into each group. There is a statistically significant difference between the rapid resolver group and the slow responders favoring amantadine effect. 51% of the patients receiving this drug had a rapid response compared to 13.6% of the placebo group.

Analysis of one objective parameter of this complex, fever was carried out in several fashions. Figure 2 is a bar graph showing the number of individuals who had short lived temperature elevations compared to those who had slower defervescence. The results were identical to the preceding figure since fever was one of the main criteria utilized.

The flowing mean temperatures shown in Figure 3 more clearly demonstrate the comparison of temperature responses between the two drug groups in the individual studies. The time intervals at the bottom of five of the 6 graphs indicate the period when there was a statistically significant difference between amantadine or placebo groups. These intervals are shown again on Table 3. Note in the Maryland prison group, Jessup, only one very late period could be shown to be significantly different. Reasons for this exception to the trend in the other study locations are unknown.

The durations of fever of 99°F or greater from onset of illness are shown in Table 4. The expected 3 days of fever due to influenzal disease was apparent in the control group. Treatment with amantadine appeared to shorten the temperature course by about 1 day. The differences between amantadine and placebo groups were significantly different in the four

TABLE III

Moving group averages of body temperature during the
5-days from onset of dosing

Study Units	Times of significant differences*
Walls Prison	33 - 90 hours
Wynne Prison	0 - 85 hours
Jessup Prison	80 hours
Richmond Prison	24 - 90 hours
Missouri Prison	28 - 108 hours
Masonic Home	17 - 70 hours

* Between the drug-dosed and placebo-dosed groups for subjects with serologically confirmed influenza.

TABLE IV

Duration (hrs.) of fever of $\geq 99^{\circ}\text{F}$ from onset
of influenza illness

	"Symmetrel" Group	Control Group	p-value
Richmond Prison	60.9	80.1	<0.05
Wynne Prison	49.8	82.1	<0.02
Walls Prison	65.1	88.3	<0.01
Jessup Prison	66.0	92.0	<0.05

TABLE V

Duration (hrs.) of fever $\geq 100^{\circ}\text{F}$ from onset
of influenza illness


	"Symmetrel" Group	Control Group	p-value
Richmond Prison	41.7	63.3	<0.02
Wynne Prison	38.5	68.8	<0.01
Walls Prison	53.5	68.4	ns
Jessup Prison	48.0		ns

prisons analyzed using 99°F as the cut-off point. However when 100°F was established as the baseline for fever, the results were less clear cut. (Table 5) The trend in all four was for less fever in the amantadine groups but the results were only significant in one Texas and the Virginia prisons.

Symptoms and signs were recorded twice daily during the early phases of each study. In a prisoner population such subjective reactions are difficult at times to interpret. Quantitation of symptoms is frequently difficult in any population group. Duration of symptoms following influenzal disease has been shown by Imboden and colleagues to often be a function of the personality involved and not the illness itself (7). Nevertheless, when symptoms and signs were analyzed in the individual groups, differences were seen. As shown previously a 50% reduction in symptom score was incorporated in the criteria for clinical response, rapid, medium or slow resolution. In these prison

FIGURE 1

CURATIVE EFFECT OF "SYMMETREL"® (AMANTADINE HCl)
COMPOSITE OF 6 DOUBLE BLIND, PLACEBO CONTROLLED CLINICAL TRIALS



populations the trend was for recorded signs and symptoms to persist for a shorter period of time in the amantadine treated than in the placebo groups. In each location a few signs or symptoms were found to be significantly more persistent in the placebo group.

Antibody Response. The effect of prophylactic amantadine on antibody response has been to reduce the number of individuals who had four fold or greater antibody responses and also to reduce the geometric mean neutralizing antibody titer. In the latter instance this was assumed to be due to reduction in antigenic mass or perhaps prevention of viral multiplication which is


TABLE VI

Shedding of A2 Influenza Virus
(Walls and Wynne Prisons)

Placebo-Treated					Amantadine-Treated						
1st Before Treatment	2nd	3rd	4th	5th	Total	1st Before Treatment	2nd	3rd	4th	5th	Total
						Days post treatment					
						Rapid Resolvers					
4/6	6/6	5/6	6/6	6/6	23/24	19/25	22/25	23/25	24/25	23/23	92/98
%67	100	83	100	100	96	69	85	85	92	100	93
						Medium Resolvers					
10/12	10/12	12/12	11/12	11/11	44/47	4/5	5/5	5/5	5/5	4/5	19/20
%83	83	100	92	100	94	80	100	100	100	80	95
						Slow Resolvers					
16/19	12/19	16/19	16/19	16/19	60/76	10/10	9/10	10/10	9/10	9/10	37/40
%84	63	84	84	84	79	100	90	100	90	90	93
						Rapid, Medium, Slow Combined					
30/37	28/37	33/37	33/37	33/36	127/147	33/40	36/40	38/40	38/40	36/38	148/158
%81	76	89	89	92	86	83	90	95	95	95	93

FIGURE 2

Defervescence



apparently needed for antibody stimulation. In the therapeutic studies included in this report no significant differences in antibody measurements were noted between placebo and amantadine treated groups. It would appear that by the time treatment was started and became effective, antibody stimulation had already begun and was not subsequently significantly altered. Jackson (5) has shown beginning antibody rise by 3 days post challenge in his volunteer studies. This was usually 48 hours after onset of illness. Assuming naturally acquired disease has a similar incubation period i.e. approximately 24 hours and amantadine therapy began to hasten recovery after another 24 hour period it appears plausible to assume antibody synthesis begins during these early days of infection and is not influenced by amantadine.

The antigenic stimulation for these antibodies is obviously the virus. One might guess that since no difference in antibody synthesis occurred between the 2 drug groups, the antigen i.e. virus persisted in both. Such indeed was the case. Table 4 illustrates this point. The data on this chart were obtained in the Walls and Wynne prisons in Texas. Virus recoveries were attempted during the first five days of participation in the study. It is apparent that amantadine treatment did not eliminate A₂ influenza virus from the pharyngeal area. Secondly virus disappearance was not associated with recovery from the disease since controls as well as amantadine treated patients were well by day 4 and most by day 3. The duration of viral carriage was not determined beyond 5 days but no evidence of lessening incidence of virus isolation by this day was evident suggesting prolonged persistence.

The results summarized here demonstrate a therapeutic efficacy of amantadine. Previous studies proved prophylactic effect. However, several questions remain to be answered. Of prime interest is the mechanism of therapeutic action. Amantadine does not have antipyretic or antihistamine activities. Perhaps the prevention of viral spread from the initial foci in